Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia

References

• Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133(14):1548–1559.
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coudé MM, Gokbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with philadelphia chromosome–positive ALL. Blood. 2016;128(6):774–782.
   PubMed Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Rituximab in B-Lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016;375(11):1044–1053.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018;19(2):240–248.
   PubMed Web of Science ®Google Scholar
• Foà R, Bassan R, Vitale A, et al. Dasatinib–blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020;383(17):1613–1623.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023;10(1):e24–e34.
   PubMed Web of Science ®Google Scholar
• Muffly L, Alvarez E, Lichtensztajn D, et al. Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. Blood Adv. 2018;2(8):895–903.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–3889.
   PubMed Web of Science ®Google Scholar
• Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100(5):653–661.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547–1555.
   PubMed Web of Science ®Google Scholar
• Jain N, Stevenson KE, Winer ES, et al. A multicenter phase I study combining venetoclax with mini-hyper-CVD in older adults with untreated and relapsed/refractory acute lymphoblastic leukemia. Blood. 2019;134(Suppl 1):3867–3867.
   Google Scholar
• Jabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with philadelphia chromosome‐negative acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2019;125(15):2579–2586.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008;113(8):2097–2101.
   PubMed Web of Science ®Google Scholar
• Saygin C, Grieselhuber N, Blachly J, et al. Outcomes of the cyclophosphamide, vincristine, prednisone (CVP)+/− rituximab (R-CVP) regimen in older patients with newly diagnosed Ph-acute lymphoblastic leukemia. Leuk Res. 2020;89:106297.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915–1925.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–2361.
   PubMed Web of Science ®Google Scholar
• Zhang W-H, Li G-Y, Ma Y-J, et al. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma. Ann Hematol. 2018;97(10):1809–1816.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Fang M, Becker PS, Linenberger M, et al. Adult low-hypodiploid acute B-Lymphoblastic leukemia with IKZF3 deletion and TP53 mutation: comparison with pediatric patients. Am J Clin Pathol. 2015;144(2):263–270.
   PubMed Web of Science ®Google Scholar
• Stanulla M, Dagdan E, Zaliova M, et al. IKZF1 defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240–1249.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685–2693.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116(12):2070–2077.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504–507.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia. 2010;24(3):521–535.
   PubMed Web of Science ®Google Scholar
• Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20(17):4540–4548.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Cazzaniga G, Van der Velden V, et al. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33(8):1910–1922.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. 2022. Acute lymphoblastic leukemia (Version 1. – April 4, 2022). [cited 2022 May 8]. https://www.nccn.org/professionals/physician_gls/pdf/all.pdf
   Google Scholar
• Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126(8):964–971.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595–1604.
   PubMed Web of Science ®Google Scholar
• Cassaday RD, Stevenson PA, Wood BL, et al. Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. Am J Hematol. 2018;93(4):546–552.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Wilson WH, Jung SH, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790–1799.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Abramson JS, et al. Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma. J Clin Oncol. 2020;38(22):2519–2529.
   PubMed Web of Science ®Google Scholar
• Lai GM, Chen YN, Mickley LA, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49(5):696–703.
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Ravandi F, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022;6(13):4006–4014.
   PubMed Web of Science ®Google Scholar
• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the International MRC UKALL XII/ECOG 2993 trial. Br J Haematol. 2012;157(4):463–471.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Beck J, Brüggemann M, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German Multicenter study group for adult ALL (GMALL). Blood. 2012;120:1493.
   Web of Science ®Google Scholar
• Hadad F, Kantarjian H, Short N, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in older adults with newly-diagnosed B-cell acute lymphoblastic leukemia: updates from a phase II trial. HemaSphere. 2022;6(S3):255.
   Google Scholar
• Advani AS, Moseley A, O'Dwyer KM, et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J Clin Oncol. 2022;40(14):1574–1582.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Bassan R, Vitale A, et al. Forty months update of the GIMEMA LAL2116 (D-Alba) protocol and ancillary LAL2217 study for newly diagnosed adult Ph + ALL. HemaSphere. 2022;6(S3):253–254.
   Google Scholar
• Cassaday R, Garcia K-L, Gooley T, et al. Dose-adjusted EPOCH + inotuzumab ozogamicin (DA-EPOCH-InO) is safe and active in adults with relapsed/refractory (R/R) B lymphoblastic leukemia (B-ALL): initial results of a phase I trial. HemaSphere. 2022;6(S3):251–252.
   Google Scholar